Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process
Mandate

Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process

August 17, 2018

In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million.

Following the transaction, Industrifonden holds approximately 23.67% of the shares in Oncopeptides.
 
Vinge’s team consisted of Dain Hård Nevonen, Rikard Lindahl and Sofie Bjärtun.

Related

Vinge advises Precise Biometrics in connection with rights issue
July 24, 2026

Vinge advises Summit Partners on its $1 billion-plus investment in Keyfactor

 Vinge has, together with Kirkland & Ellis, advised Summit Partners in connection with a strategic growth investment in Keyfactor, a leader in trust infrastructure. The investment will help accelerate the company's global scale and growth initiatives, enabling product innovation, geographic expansion, team building and strategic acquisitions.
July 20, 2026

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

 Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026